각막이식 거부반응 고위험군에서 전층각막이식술 후 저용량 사이클로스포린 투약에 따른 이식실패율 = The Efficacy of Low-Dose Systemic Cyclosporine for Graft Failure after Penetrating Keratoplasty in High-Risk Group

다국어 초록 (Multilingual Abstract)

Purpose: To investigate the effect of low-dose systemic cyclosporine A (CsA) in preventing graft failure after high-risk penetrating keratoplasty (PKP). Methods: In this retrospective study, 36 eyes of 25 patients who underwent PKP were evaluated. At 24 months postoperatively, the failure rate in the CsA group (n = 19) was compared to the control group (n = 17). For subgroup analysis, the failure rate in the CsA group (n = 9) and control group (n = 9) was compared in patients who underwent a repeat PKP. The patients’ side-effect profile was also collected. Results: The median follow-up in the CsA group was 32.8 months and 28.9 months in the control group. Graft failure occurred in 31.6% CsA patients and in 68.4% control patients (p = 0.311). In patients with repeat PKP, the failure rate in the CsA group was significantly lower than the control group (22.2% vs. 77.8%, p = 0.018). In one case (5.26%), CsA was discontinued due to gastroinstestinal discomfort. Conclusions: Low-dose CsA was not beneficial compared to conventional therapy in high-risk PKP patients. However, in the repeat PKP subgroup, the incidence of graft failure was lower with low-dose CsA than with conventional therapy. Although further study is necessary, adding low-dose CsA might be beneficial for repeat PKP patients. J Korean Ophthalmol Soc 2014;55(1):13-19

참고문헌 (Reference)

1 김은철, "전층각막이식의 거부반응" 대한안과학회 44 (44): 6-295, 2003

2 Pescovitz MD, "Twohour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts" 16 : 378-382, 2002

3 Keenan TD, "Trends in corneal graft surgery in the UK" 95 : 468-472, 2011

4 Robert PY, "Treatment with cyclosporin A, with low doses, in high-risk penetrating keratoplasties. A bi-centric study of 90 cases" 20 : 507-514, 1997

5 Hill JC, "The use of systemic cyclosporin a in human corneal transplantation:a preliminary report" 62 : 337-344, 1986

6 Joseph A, "Tacrolimus immunosuppression in high-risk corneal grafts" 91 : 51-55, 2007

7 Reinhard T, "Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial" 239 : 367-372, 2001

8 Hill JC, "Systemic cyclosporine in high-risk keratoplasty. Shortversus long-term therapy" 101 : 128-133, 1994

9 Poon AC, "Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study" 85 : 1464-1469, 2001

10 Rumelt S, "Systemic cyclosporin A in high failure risk, repeated corneal transplantation" 86 : 988-992, 2002

11 Reinhard T, "Systemic ciclosporin A in high-risk keratoplasties" 234 (234): S115-S121, 1996

12 Chatel MA, "Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk" 150 : 179-184, 2010

13 Boisjoly HM, "Risk factors of corneal graft failure" 100 : 1728-1735, 1993

14 Williams KA, "Risk factors for human corneal graft failure within the Australian corneal graft registry" 86 : 1720-1724, 2008

15 Fasolo A, "Risk factors for graft failure after penetrating keratoplasty: 5-year follow-up from the corneal transplant epidemiological study" 30 : 1328-1335, 2011

16 Shimazaki J, "Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation" 152 : 33-9.e1-, 2011

17 Borghi A, "Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients" 51 : 1512-1516, 2012

18 Reinhard T, "Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor" 94 : 496-500, 1997

19 Anshu A, "Postoperative risk factors influencing corneal graft survival in the Singapore Corneal Transplant Study" 151 : 442-8.e1-, 2011

20 Tan DT, "Penetrating keratoplasty in Asian eyes: the Singapore Corneal Transplant Study" 115 : 975-82. e1-, 2008

21 Weisbrod DJ, "Outcomes of repeat penetrating keratoplasty and risk factors for graft failure" 22 : 429-434, 2003

22 Keown P, "Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies:report from the International Neoral TDM Advisory Consensus Meeting" 30 : 1645-1649, 1998

23 Birnbaum F, "Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study" 23 : 2063-2070, 2009

24 Patel J, "Minimization of immunosuppression:transplant immunology" 20 (20): 48-54, 2008

25 Thompson RW Jr, "Long-term graft survival after penetrating keratoplasty" 110 : 1396-1402, 2003

26 Starzl TE, "Liver transplantation with use of cyclosporin a and prednisone" 305 : 266-269, 1981

27 Woods JE, "High-dosage intravenously administered methylprednisolone in renal transplantation. A preliminary report" 223 : 896-899, 1973

28 Völker-Dieben HJ, "Hierarchy of prognostic factors for corneal allograft survival" 15 : 11-18, 1987

29 Williams KA, "Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry" 99 : 403-414, 1992

30 Luengo-Gimeno F, "Evolution of deep anterior lamellar keratoplasty" 9 : 98-110, 2011

31 Lee WB, "Descemet's stripping endothelial keratoplasty: safety and outcomes: a report by the American Academy of Ophthalmology" 116 : 1818-1830, 2009

32 Algros MP, "Danger of systemic cyclosporine for corneal graft" 21 : 613-614, 2002

33 Graham RM, "Cyclosporine: mechanisms of action and toxicity" 61 : 308-313, 1994

34 Lichtiger S, "Cyclosporine in severe ulcerative colitis refractory to steroid therapy" 330 : 1841-1845, 1994

35 Calne RY, "Cyclosporin A in patients receiving renal allografts from cadaver donors" 2 : 1323-1327, 1978

36 Wagoner MD, "Corneal transplant survival after onset of severe endothelial rejection" 114 : 1630-1636, 2007